التفاصيل البيبلوغرافية
| العنوان: |
Muscle loss contributes to higher morbidity and mortality in COPD: An analysis of national trends. |
| المؤلفون: |
Attaway, Amy H., Welch, Nicole, Hatipoğlu, Umur, Zein, Joe G., Dasarathy, Srinivasan |
| المصدر: |
Respirology; Jan2021, Vol. 26 Issue 1, p62-71, 10p |
| مصطلحات موضوعية: |
OBSTRUCTIVE lung diseases, MEDICAL care costs, MUSCLES, TREND analysis, HOSPITAL mortality |
| مستخلص: |
Background and objective: COPD is the third most common cause of death worldwide and fourth most common in the United States. In hospitalized patients with COPD, mortality, morbidity and healthcare resource utilization are high. Skeletal muscle loss is frequent in patients with COPD. However, the impact of muscle loss on adverse outcomes has not been systematically evaluated. We tested the hypothesis that patients hospitalized for COPD exacerbation with, compared to those without, a secondary diagnosis of muscle loss phenotype (all ICD‐9 codes associated with muscle loss including cachexia) will have higher mortality and cost of care. Methods: The NIS database of hospitalized patients in 2011 (1 January–31 December) in the United States was used. The impact of a muscle loss phenotype on in‐hospital mortality, LOS and cost of care for each of the 174 808 hospitalizations for COPD exacerbations was analysed. Results: Of the subjects admitted for a COPD exacerbation, 12 977 (7.4%) had a secondary diagnosis of muscle loss phenotype. A diagnosis of muscle loss phenotype was associated with significantly higher in‐hospital mortality (14.6% vs 5.7%, P < 0.001), LOS (13.3 + 17.1 vs 5.7 + 7.6, P < 0.001) and median hospital charge per patient ($13 947 vs $6610, P < 0.001). Multivariate regression analysis showed that muscle loss phenotype increased mortality by 111% (95% CI: 2.0–2.2, P < 0.001), LOS by 68.4% (P < 0.001) and the direct cost of care by 83.7% (P < 0.001) compared to those without muscle loss. Conclusion: In‐hospital mortality, LOS and healthcare costs are higher in patients with COPD exacerbations and a muscle loss phenotype. Using a large national data set of patients admitted for a COPD exacerbation with and without muscle loss phenotype, we showed that mortality, LOS and cost are considerably higher in patients with muscle loss phenotype. We demonstrated the need for targeted interventions to improve outcomes for patients with COPD. See relatedEditorial [ABSTRACT FROM AUTHOR] |
|
Copyright of Respirology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
